ArticleEuropean journal of dermatology : EJD2021

Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients.

Xiuting Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.